USD 9.05
(-0.54%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | 611 Thousand USD | -2.24% |
2022 | 625 Thousand USD | -99.51% |
2021 | 128.6 Million USD | 2.72% |
2020 | 125.2 Million USD | 67.99% |
2019 | 74.53 Million USD | 2.8% |
2018 | 72.5 Million USD | 0.89% |
2017 | 71.86 Million USD | 371.05% |
2016 | 15.25 Million USD | 5.36% |
2015 | 14.48 Million USD | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q2 | 125.29 Million USD | -4.1% |
2024 Q1 | 130.65 Million USD | 0.0% |
2023 Q4 | 611 Thousand USD | -17.54% |
2023 Q3 | 741 Thousand USD | 125.23% |
2023 Q1 | 407 Thousand USD | -34.88% |
2023 Q2 | 329 Thousand USD | -19.16% |
2023 FY | 611 Thousand USD | -2.24% |
2022 Q3 | 891 Thousand USD | -99.3% |
2022 FY | 625 Thousand USD | -99.51% |
2022 Q1 | 126.95 Million USD | -1.29% |
2022 Q2 | 127.48 Million USD | 0.42% |
2022 Q4 | 625 Thousand USD | -29.85% |
2021 Q3 | 126.54 Million USD | 0.4% |
2021 Q4 | 128.6 Million USD | 1.63% |
2021 FY | 128.6 Million USD | 2.72% |
2021 Q1 | 125.58 Million USD | 0.31% |
2021 Q2 | 126.04 Million USD | 0.37% |
2020 FY | 125.2 Million USD | 67.99% |
2020 Q1 | 104.65 Million USD | 40.42% |
2020 Q4 | 125.2 Million USD | 19.23% |
2020 Q3 | 105.01 Million USD | 0.06% |
2020 Q2 | 104.94 Million USD | 0.28% |
2019 FY | 74.53 Million USD | 2.8% |
2019 Q1 | 72.68 Million USD | 0.25% |
2019 Q2 | 72.86 Million USD | 0.26% |
2019 Q3 | 74.26 Million USD | 1.92% |
2019 Q4 | 74.53 Million USD | 0.36% |
2018 Q4 | 72.5 Million USD | 0.25% |
2018 FY | 72.5 Million USD | 0.89% |
2018 Q1 | 71.96 Million USD | 0.14% |
2018 Q2 | 72.13 Million USD | 0.24% |
2018 Q3 | 72.31 Million USD | 0.25% |
2017 Q2 | - USD | 0.0% |
2017 Q1 | - USD | -100.0% |
2017 FY | 71.86 Million USD | 371.05% |
2017 Q4 | 71.86 Million USD | 0.0% |
2017 Q3 | - USD | 0.0% |
2016 FY | 15.25 Million USD | 5.36% |
2016 Q4 | 15.25 Million USD | 0.0% |
2015 FY | 14.48 Million USD | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
ANI Pharmaceuticals, Inc. | 309.66 Million USD | 99.803% |
Aquestive Therapeutics, Inc. | 91.07 Million USD | 99.329% |
Collegium Pharmaceutical, Inc. | 489.96 Million USD | 99.875% |
Dynavax Technologies Corporation | 252.41 Million USD | 99.758% |
Esperion Therapeutics, Inc. | 501.54 Million USD | 99.878% |
Cosmos Health Inc. | 3.03 Million USD | 79.87% |
Pacira BioSciences, Inc. | 513.79 Million USD | 99.881% |
PainReform Ltd. | 30 Thousand USD | -1936.667% |
Sunshine Biopharma, Inc. | 539.03 Thousand USD | -13.351% |
Sunshine Biopharma, Inc. | 539.03 Thousand USD | -13.351% |
SCYNEXIS, Inc. | 12.15 Million USD | 94.975% |
Safety Shot Inc | 304.9 Thousand USD | -100.389% |
China SXT Pharmaceuticals, Inc. | 117.12 Thousand USD | -421.647% |
Alpha Teknova, Inc. | 13.25 Million USD | 95.389% |
Embecta Corp. | 1.62 Billion USD | 99.962% |
Bright Green Corporation | 201.78 Thousand USD | -202.801% |
Intra-Cellular Therapies, Inc. | 13.32 Million USD | 95.415% |
Journey Medical Corporation | 14.62 Million USD | 95.821% |
Procaps Group, S.A. | 28.41 Million USD | 97.849% |
Theratechnologies Inc. | 51.26 Million USD | 98.808% |
Harrow Health, Inc. | 183.17 Million USD | 99.666% |
Sonoma Pharmaceuticals, Inc. | 87 Thousand USD | -602.299% |
Biofrontera Inc. | 804 Thousand USD | 24.005% |
DURECT Corporation | 2.7 Million USD | 77.387% |
Supernus Pharmaceuticals, Inc. | 33.19 Million USD | 98.159% |
Cronos Group Inc. | 1.55 Million USD | 60.808% |
Ironwood Pharmaceuticals, Inc. | 498.3 Million USD | 99.877% |
Kala Pharmaceuticals, Inc. | 34.19 Million USD | 98.213% |
RedHill Biopharma Ltd. | 455 Thousand USD | -34.286% |
Organogenesis Holdings Inc. | 60.74 Million USD | 98.994% |
Guardion Health Sciences, Inc. | - USD | -Infinity% |
Cumberland Pharmaceuticals Inc. | 12.78 Million USD | 95.221% |
Radius Health, Inc. | 339.66 Million USD | 99.82% |
Universe Pharmaceuticals INC | - USD | -Infinity% |
ProPhase Labs, Inc. | 10.25 Million USD | 94.044% |
Phibro Animal Health Corporation | 458.28 Million USD | 99.867% |
Procaps Group S.A. | 28.41 Million USD | 97.849% |
Alvotech | 1.02 Billion USD | 99.941% |
TherapeuticsMD, Inc. | 6.53 Million USD | 90.646% |
Viatris Inc. | 16.18 Billion USD | 99.996% |
Rockwell Medical, Inc. | 8.29 Million USD | 92.632% |
Aytu BioPharma, Inc. | 10.87 Million USD | 94.383% |
SIGA Technologies, Inc. | 335.99 Thousand USD | -81.85% |
Tilray Brands, Inc. | 287.93 Million USD | 99.788% |
Lifecore Biomedical, Inc. | 120.51 Million USD | 99.493% |
Shineco, Inc. | 10.01 Million USD | 93.901% |
PetIQ, Inc. | 437.82 Million USD | 99.86% |
Regencell Bioscience Holdings Limited | - USD | -Infinity% |
Incannex Healthcare Limited | 210 Thousand USD | -190.952% |
Neurocrine Biosciences, Inc. | 258.3 Million USD | 99.763% |
Alimera Sciences, Inc. | 64.48 Million USD | 99.053% |
Silver Spike Investment Corp. | - USD | -Infinity% |
Assertio Holdings, Inc. | 38.51 Million USD | 98.414% |
Shuttle Pharmaceuticals Holdings, Inc. | 135.08 Thousand USD | -352.294% |
Petros Pharmaceuticals, Inc. | 6.85 Million USD | 91.09% |
Clever Leaves Holdings Inc. | 720 Thousand USD | 15.139% |
Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -2617.488% |
Avadel Pharmaceuticals plc | 32.75 Million USD | 98.135% |
Hempacco Co., Inc. | 5.93 Million USD | 89.698% |
Talphera, Inc. | - USD | -Infinity% |
Alvotech | 1.02 Billion USD | 99.941% |
Eagle Pharmaceuticals, Inc. | 56.21 Million USD | 98.913% |
Lantheus Holdings, Inc. | 616.12 Million USD | 99.901% |
Currenc Group, Inc. | 2.5 Million USD | 75.628% |
Kamada Ltd. | 7.43 Million USD | 91.785% |
Indivior PLC | 235.66 Million USD | 99.741% |
Evoke Pharma, Inc. | 5 Million USD | 87.78% |
Flora Growth Corp. | 942 Thousand USD | 35.138% |
Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -2617.488% |
Evolus, Inc. | 120.35 Million USD | 99.492% |
HUTCHMED (China) Limited | 48.18 Million USD | 98.732% |
Amphastar Pharmaceuticals, Inc. | 589.19 Million USD | 99.896% |
Akanda Corp. | 2.49 Million USD | 75.532% |